- Trials with a EudraCT protocol (41)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
41 result(s) found for: Galantamine.
Displaying page 1 of 3.
EudraCT Number: 2007-000762-20 | Sponsor Protocol Number: THR-4109-C-302 | Start Date*: 2007-09-05 | |||||||||||
Sponsor Name:Theracos, Inc. | |||||||||||||
Full Title: A Phase II Randomized, Double-Blind, Double-Dummy, Parallel Group, Placebo Controlled Study of Galantamine + Sertraline, Galantamine or Sertraline in Obese Subjects | |||||||||||||
Medical condition: Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002780-27 | Sponsor Protocol Number: GAL-ALZ-3005 | Start Date*: 2008-08-26 | |||||||||||
Sponsor Name:Janssen Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-severe Alzheimer’s Disease | |||||||||||||
Medical condition: Mild to moderately severe Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) LT (Completed) LV (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) AT (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004393-41 | Sponsor Protocol Number: 2004 | Start Date*: 2015-05-13 |
Sponsor Name:CUB Hospital Erasme | ||
Full Title: A double-blind, placebo-controlled study of the impact of prophylactic treatment with Galantamine 8mg of cognitive impairment during an electroconvulsive therapy (ECT) in patients with major depre... | ||
Medical condition: The subjects enrolled in the study will be major patients with major depressive disorder diagnosed according to DSM-IV, receiving electroconvulsive therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-006011-62 | Sponsor Protocol Number: NL38747.048.11 | Start Date*: 2012-02-08 | |||||||||||
Sponsor Name:Slotervaart Hospital | |||||||||||||
Full Title: The ACER-study - the effects of galantamine on the variability and stability of walking among patients with Alzheimer's disease. | |||||||||||||
Medical condition: Dementia of the Alzheimer type | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001174-25 | Sponsor Protocol Number: NC501/SC01904 | Start Date*: Information not available in EudraCT |
Sponsor Name:Neurocure Ltd | ||
Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF A COMBINATION OF GALANTAMINE (AN ACETYLCHOLINESTERASE INHIBITOR) PLUS TRIMIPRAMINE IN SMOKING CESSATION | ||
Medical condition: Healthy subjects who are smokers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005472-27 | Sponsor Protocol Number: 70639 | Start Date*: 2009-03-30 |
Sponsor Name:Medizinische Universität Innsbruck | ||
Full Title: Die antidementive Therapie mit Acetylcholinesteraseinhibitoren: Untersuchung von Plasmakonzentrationen, Arzneimittelinteraktionen und Therapieeffekt in Abhängigkeit von genetischen Polymorphismen | ||
Medical condition: Anhand der vorliegenden Studie soll untersucht werden, ob genetische Polymorphismen im CYP2D6-, im MDR1- oder im ACHE Gen mit sub- bzw. supratherapeutischen Wirkstoffspiegeln im Plasma, mit relevan... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006278-13 | Sponsor Protocol Number: NL24092.042.08 | Start Date*: 2009-02-04 | ||||||||||||||||
Sponsor Name:UMCG | ||||||||||||||||||
Full Title: Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations. | ||||||||||||||||||
Medical condition: patients with advanced (>5 years) Parkinson's disease and visual hallucinations. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000569-61 | Sponsor Protocol Number: CHUBX2016/27 | Start Date*: 2021-12-20 |
Sponsor Name:CHU de Bordeaux | ||
Full Title: Comparison of therapeutic strategies with Cholinesterase Inhibitors: stop or still (SOS) trial | ||
Medical condition: Alzheimer disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003359-19 | Sponsor Protocol Number: GALPED1001 | Start Date*: 2007-08-07 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: An open-label study of two single oral doses of galantamine, examining the pharmacokinetics, safety, and tolerability in children with Down syndrome | |||||||||||||
Medical condition: Children with Down syndrom | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013689-18 | Sponsor Protocol Number: GALALZ4041 | Start Date*: 2010-05-11 | |||||||||||
Sponsor Name:Janssen-Cilag S.A. | |||||||||||||
Full Title: ESTUDIO FASE IV PARA LA EVALUACIÓN DEL EFECTO MODULADOR DE LA GALANTAMINA (REMINYL CLP®) SOBRE EL RITMO CIRCADIANO DE PACIENTES CON ENFERMEDAD DE ALZHEIMER MODERADA | |||||||||||||
Medical condition: Enfermedad de Alzheimer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002614-10 | Sponsor Protocol Number: 10112 | Start Date*: 2005-05-17 |
Sponsor Name:Lundbeck Limited | ||
Full Title: A 1-Year Randomised, Double-Blind Placebo-Controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients with Alzheimer’s Disease | ||
Medical condition: Probable Alzheimer's Disease of moderate severity. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-011093-15 | Sponsor Protocol Number: 06173915 | Start Date*: 2009-11-16 | ||||||||||||||||
Sponsor Name:Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology | ||||||||||||||||||
Full Title: The role of the neurotransmitters dopamine and acetylcholine in the interaction of selective attention and working memory. | ||||||||||||||||||
Medical condition: Healthy volunteers | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-003214-15 | Sponsor Protocol Number: VP-AD-302 | Start Date*: 2005-12-12 |
Sponsor Name:Voyager Pharmaceutical Corporation | ||
Full Title: A DOUBLE-BLIND PLACEBO- CONTROLLED STUDY OF VP4896 FOR THE TREATMENT OF MILD-TO-MODERATE ALZHEIMER'S DISEASE | ||
Medical condition: | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) LT (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002653-30 | Sponsor Protocol Number: EVP-6124-025 | Start Date*: 2014-03-18 | ||||||||||||||||
Sponsor Name:EnVivo Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer’s Disease Currently or Previou... | ||||||||||||||||||
Medical condition: Mild to moderate Alzheimer's disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004335-36 | Sponsor Protocol Number: ANAVEX2-73-PDD-001 | Start Date*: 2018-07-04 |
Sponsor Name:Anavex Life Sciences Corp. | ||
Full Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients. | ||
Medical condition: Cognition in Parkinson’s Disease with dementia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002678-29 | Sponsor Protocol Number: ANAVEX2-73-PDD-EP-001 | Start Date*: 2019-12-05 | ||||||||||||||||
Sponsor Name:Anavex Life Sciences Corp. | ||||||||||||||||||
Full Title: Open Label Extension Study for Patients with Parkinson’s Disease with Dementia Previously Enrolled in ANAVEX2-73-PDD-001 Study for Continued Safety Assessment | ||||||||||||||||||
Medical condition: Cognition in Parkinson’s Disease with Dementia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002106-52 | Sponsor Protocol Number: CANBiS-AD | Start Date*: 2020-03-19 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: CANnabidiol for Behavioural Symptoms in Alzheimer’s Disease | |||||||||||||
Medical condition: Alzheimer's disease patients with BPSD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003567-66 | Sponsor Protocol Number: T817MAEU201 | Start Date*: 2019-06-11 | ||||||||||||||||
Sponsor Name:FUJIFILM Toyama Chemical Co., Ltd. | ||||||||||||||||||
Full Title: A Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T 817MA in patients with mild cognitive impairment due to Alzheimer... | ||||||||||||||||||
Medical condition: Mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) ES (Ongoing) HU (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005529-34 | Sponsor Protocol Number: TRx-237-007 | Start Date*: 2012-12-28 | |||||||||||
Sponsor Name:TauRx Therapeutics Ltd | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotem... | |||||||||||||
Medical condition: behavioral variant Frontotemporal Dementia (bvFTD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) NL (Completed) IT (Completed) FI (Completed) PL (Completed) ES (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005031-24 | Sponsor Protocol Number: 1289.5 | Start Date*: 2014-12-04 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compare... | |||||||||||||
Medical condition: Patients with diagnosis of AD according to the following criteria: • Symptoms noticed by the patients and/or informant • Cognitive testing confirming symptoms • Biomarker evidence of AD patholog... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) PT (Completed) ES (Completed) BE (Completed) AT (Completed) NL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.